Related Experiment Video

Updated: Aug 16, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Inhibition of RAAS--when is it too much?

Pablo Navarro1, Robert Moskowitz, Thierry H Le Jemtel

  • 1Room G-46 Forchheimer Building, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.

Current Heart Failure Reports
|July 23, 2005
PubMed

Insights

Deactivating the renin-angiotensin-aldosterone system (RAAS) benefits heart attack and heart failure patients. This review examines current treatments like angiotensin-converting enzyme inhibition (ACEI) and addresses remaining questions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in cardiovascular regulation.
  • Deactivating the RAAS is a proven therapeutic strategy for patients with myocardial infarction and chronic heart failure.
  • Extensive clinical trial data exists for angiotensin-converting enzyme inhibition (ACEI) in RAAS deactivation.

Purpose of the Study:

  • To review the established benefits of RAAS deactivation in post-myocardial infarction and chronic heart failure patients.
  • To evaluate the efficacy of angiotensin receptor blockade (ARB) as an alternative to ACEI for RAAS deactivation.
  • To identify and address unresolved clinical questions regarding RAAS inhibition therapies.

Main Methods:

  • Review of placebo-controlled randomized trials focusing on ACEI.
  • Analysis of studies comparing ARB with ACEI or placebo.
  • Discussion of aldosterone receptor blockade in relevant patient populations.

Main Results:

  • ACEI is a well-established method for RAAS deactivation with proven benefits.
  • The hypothesis that ARBs offer superior RAAS deactivation compared to ACEI has not been substantiated by clinical evidence.
  • Aldosterone receptor blockade also demonstrates efficacy in specific patient groups.

Conclusions:

  • RAAS deactivation remains a cornerstone of therapy for myocardial infarction and heart failure.
  • While ACEI is a reliable approach, further research is needed to clarify optimal strategies and address remaining clinical uncertainties.
  • The role and comparative effectiveness of different RAAS-blocking agents require ongoing investigation.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...